Trexquant Investment LP Zai Lab LTD Transaction History

Trexquant Investment LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$13.72 - $21.55 $44,425 - $69,778	3,238 Added 4.83%	70,283 $1.22 Million
Q1 2024 May 14, 2024	BUY	$15.95 - $26.8 $735,741 - $1.24 Million	46,128 Added 220.53%	67,045 $1.07 Million
Q4 2023 Feb 09, 2024	BUY	$22.97 - $30.58 $480,463 - $639,641	20,917 New	20,917 $571,000
Q4 2022 Feb 13, 2023	BUY	$22.28 - $38.71 $712,269 - $1.24 Million	31,969 Added 108.62%	61,402 $1.89 Million
Q3 2022 Nov 14, 2022	SELL	$34.2 - $51.69 $421,207 - $636,614	-12,316 Reduced 29.5%	29,433 $1.01 Million
Q2 2022 Aug 11, 2022	BUY	$23.14 - $49.68 $966,071 - $2.07 Million	41,749 New	41,749 $1.45 Million
Q4 2021 Feb 14, 2022	SELL	$54.9 - $105.21 $592,041 - $1.13 Million	-10,784 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$105.0 - $178.37 $925,575 - $1.57 Million	8,815 Added 447.69%	10,784 $1.14 Million
Q2 2021 Aug 12, 2021	BUY	$125.11 - $180.0 $54,172 - $77,940	433 Added 28.19%	1,969 $348,000
Q1 2021 May 13, 2021	SELL	$126.27 - $191.71 $140,285 - $212,989	-1,111 Reduced 41.97%	1,536 $205,000
Q4 2020 Feb 11, 2021	BUY	$81.94 - $135.34 $216,895 - $358,244	2,647 New	2,647 $358,000

121

46.7M

223K

588K

Ticker ZLAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,908,704
Market Cap $2.57B
Description
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA f...

Get notified when there are updates to the investment portfolio of Trexquant Investment LP, based on Form 13F filings with the SEC.

Stay updated on Trexquant Investment LP with notifications on news.